Jose D G, Minty C C
Med J Aust. 1980 Oct 4;2(7):390-4. doi: 10.5694/j.1326-5377.1980.tb131881.x.
The effect of the immunomodulating drug levamisole was tested in 33 patients with frequently recurring attacks of herpes labialis or herpes genitalis. All patients had suffered monthly recurrent attacks for at least six months, but were otherwise healthy. Patients were randomly allocated to receive levamisole tablets, 2.5 mg/kg orally, on two consecutive days each week for 26 weeks, or placebo tablets taken for a similar time. The tablets were reversed for a second consecutive six-month period. Seven of 21 patients (33%) with recurrent herpes genitalis infection showed complete response and 10 (47%) showed a partial response while receiving levamisole. Three of 21 patients (14%) showed a partial response on placebo. Six of 12 patients (50%) with herpes labialis showed complete or partial responses, with three partial responses on placebo. Frequent minor drug side effects were seen, and therapy was ceased in one patient. No episodes of leucopenia or agranulocytosis were encountered. Levamisole produces a significantly better reduction in frequency, duration and severity of herpes attacks than placebo, particularly after the initial eight weeks of administration.
对33例复发性唇疱疹或生殖器疱疹患者进行了免疫调节药物左旋咪唑的疗效测试。所有患者每月复发至少六个月，但其他方面健康。患者被随机分配，一组连续26周每周连续两天口服2.5mg/kg左旋咪唑片，另一组服用相似时间的安慰剂片。在接下来连续的六个月期间，两组药物互换。21例复发性生殖器疱疹感染患者中，7例（33%）在接受左旋咪唑治疗时显示完全缓解，10例（47%）显示部分缓解。21例患者中有3例（14%）在服用安慰剂时显示部分缓解。12例唇疱疹患者中有6例（50%）显示完全或部分缓解，服用安慰剂时有3例部分缓解。观察到频繁的轻微药物副作用，1例患者停止治疗。未出现白细胞减少或粒细胞缺乏症。与安慰剂相比，左旋咪唑在疱疹发作的频率、持续时间和严重程度方面有显著更好的降低效果，尤其是在给药的最初八周后。
